<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131325</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107AUS20</org_study_id>
    <nct_id>NCT01131325</nct_id>
  </id_info>
  <brief_title>Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations</brief_title>
  <acronym>MACS1148</acronym>
  <official_title>A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the number of European Leukemia Network (ELN)guideline defined
      treatment failure events from time of study entry in CML-CP patients with low imatinib trough
      concentrations treated with nilotinib.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the number of ELN-guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations (&lt;850 ng/mL) treated with nilotinib.</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of ELN-defined optimal responses on nilotinib.</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate and time to loss of CCyR, MMR and CMR on nilotinib.</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to and duration of the CCyR, MMR and CMR achieved on nilotinib.</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine EFS, PFS and OS with up to 2 years of nilotinib treatment and overall safety profile</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>CML</condition>
  <condition>Philadelphia Chromosome Positive (Ph+)</condition>
  <condition>Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>AMN107</other_name>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph+ CML-CP within 12 months of diagnosis

          -  Imatinib 400 mg qd for up to 12 months

          -  Imatinib trough plasma concentration &lt;850 ng/mL

          -  Patient that have met response milestones including:

               1. CHR and at least minor CyR (Ph+ ≤65%) at 3 months from diagnosis

               2. At least pCyR at 6 months from diagnosis (Ph+ ≤35%)

               3. CCyR at 12 months from diagnosis

        Exclusion Criteria:

          -  Prior documented failure events including:

          -  Loss of CHR or CCyR

          -  Less than CHR (stable disease or disease progression) at 3 months after diagnosis

          -  No CyR at 6 months after diagnosis

          -  Less than PCyR at 12 months after diagnosis

          -  Prior accelerated phase or blast phase CML

          -  Previously documented T315I mutation

          -  Previous treatment with any other tyrosine kinase inhibitor except for imatinib.

          -  Patients who had any other treatment for CML (transplant) except imatinib, hydroxyurea
             and/or anagrelide

          -  Impaired cardiac function (refer to Section 5.2 for details)

          -  Patients receiving therapy with strong inhibitors of CYP3A4 or medications that
             prolong the QT interval and cannot be either discontinued or switched to a different
             medication prior to starting study drug.

          -  Any other malignancy that is clinically significant or requires active intervention.

          -  Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from
             prior surgery.

          -  Treatment with other investigational agents within 30 days of Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada CCC of Nevada (1)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of the High Plains</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Philadelphia chromosome positive</keyword>
  <keyword>Ph+</keyword>
  <keyword>chronic myelogenous leukemia chronic phase</keyword>
  <keyword>CML-CP</keyword>
  <keyword>low imatinib trough levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

